Population homogeneity for the antibody response to COVID-19 Comirnaty vaccine is only reached after the second dose

Joao F Viana; Marie-Louise Bergman; Ligia A Gonçalves; Nadia Duarte; Teresa Penha Coutinho; Patricia C Borges; Christian Diwo; Rute Castro; Paula Matoso; Vanessa Malheiro; Ana Brennand; Lindsay Kosack; Onome Akpogheneta; Joao M Figueira; Conceiçao Cardoso; Ana M Casaca; Paula M Alves; Telmo Nunes; Carlos Penha-Gonçalves; Jocelyne Demengeot.
Preprint en Inglés | PREPRINT-MEDRXIV | ID: ppmedrxiv-21253680

Documentos relacionados

  1. Enhanced SARS-CoV-2 IgG durability following COVID-19 mRNA booster vaccination and comparison of BNT162b2 with mRNA-1273.
  2. Qualitative assessment of anti-SARS-CoV-2 spike protein immunogenicity (QUASI) after COVID-19 vaccination in older people living with HIV.
  3. Loss of Pfizer (BNT162b2) Vaccine-Induced Antibody Responses against the SARS-CoV-2 Omicron Variant in Adolescents and Adults.
  4. Spheromers reveal robust T cell responses to the Pfizer/BioNTech vaccine and attenuated peripheral CD8<sup>+</sup> T cell responses post SARS-CoV-2 infection.
  5. Elevated CD21<sup>low</sup> B Cell Frequency Is a Marker of Poor Immunity to Pfizer-BioNTech BNT162b2 mRNA Vaccine Against SARS-CoV-2 in Patients with Common Variable Immunodeficiency.
  6. mRNA COVID-19 Vaccine-Associated Subserosal Eosinophilic Gastroenteritis: A Case Report.
  7. Correlates of protection and determinants of SARS-CoV-2 breakthrough infections 1 year after third dose vaccination.
  8. Humoral and cellular immune memory to four COVID-19 vaccines.
  9. COVID-19 Adenoviral Vector Vaccination Elicits a Robust Memory B Cell Response with the Capacity to Recognize Omicron BA.2 and BA.5 Variants.
  10. Humoral immunity and B-cell memory in response to SARS-CoV-2 infection and vaccination.